Opzelura Delivers Rapid, Meaningful Relief in Phase 3b Trial
Incyte has unveiled promising new data from its phase 3b TRuE-AD4 study of Opzelura (ruxolitinib cream 1.5%) in adults with moderate atopic dermatitis (AD), showing swift and substantial improvements across key clinical signs and symptoms – most notably itch relief as early as day 2.
At week 8, the trial met both co-primary endpoints. Seventy per cent of patients treated with Opzelura achieved EASI75 (a ≥75% improvement on the Eczema Area and Severity Index), while 61.3% reached Investigator’s Global Assessment–Treatment Success (IGA-TS).
Both outcomes were significantly higher than those observed in the vehicle group, underscoring the cream’s efficacy in this population.
Rapid itch relief and sustained symptom control
Beyond these headline results, TRuE-AD4 captured the speed of symptom relief.
Significant itch reduction was recorded at day 2, with improvements reported within 15 minutes of application – an important differentiator for a condition where pruritus often drives distress, sleep disruption and reduced quality of life.
By week 8, 62.5% of patients achieved a ≥4-point improvement on the Itch Numeric Rating Scale, reinforcing the therapy’s impact on one of AD’s most burdensome symptoms.
Patient-reported outcomes move in the right direction
Clinical gains translated into everyday benefits.
Participants reported improvements on the Patient-Oriented Eczema Measure (POEM) and the Dermatology Life Quality Index (DLQI), indicating that reductions in signs and itch were accompanied by better day-to-day functioning and wellbeing.
Expert and company perspectives
Incyte’s Group Vice President for Inflammation & Autoimmunity said the TRuE-AD4 data further strengthen the safety and efficacy profile of Opzelura and its ability to control key signs and symptoms of moderate AD, including bothersome itch.
Adding a clinician’s view, the Professor of Dermatology and Allergy at Augsburg University Hospital highlighted that these results offer compelling support for Opzelura’s utility in patients with moderate AD who have limited topical options – owing to inadequate responses or intolerance to topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) – and who might otherwise be steered towards systemic therapy.
Regulatory next steps in Europe
Incyte plans to use these data to support a Type-II variation application in Europe for ruxolitinib cream 1.5% (Opzelura), aiming to expand access for adults with moderate AD who require effective, nonsteroidal topical treatment options.
Conclusion
TRuE-AD4 paints a clear picture: Opzelura provides rapid itch relief – within minutes in some cases – and robust improvements in disease severity by week 8, with meaningful gains reported by patients in daily life.
With co-primary endpoints met and multiple secondary measures moving in the right direction, the findings bolster confidence in ruxolitinib cream’s role as a nonsteroidal topical option for adults with moderate atopic dermatitis – particularly those underserved by existing topical therapies and keen to avoid a step up to systemic treatment.
News Credits: Opzelura shows strong results in phase 3b trial for moderate atopic dermatitis
Things you may also like:
- Fezolinetant Shows Real-World Gains for Menopausal Symptoms Study
- ENA Respiratory Raises US$22.4m to Advance Once-Weekly Antiviral Nasal Spray
- Mr Whippy Bites Into Bakery With £15m Sheffield Factory